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Background: The detection of cytomegalovirus (CMV) DNA in blood is a key feature of the virological surveillance
of immunocompromised patients.
Methods: The QIAsymphony RGQ system (QIAGEN S.A.S., France) combines the extraction/distribution steps on
QIAsymphony SP/AS instruments with amplification on a Rotor-Gene Q RT-PCR machine. This system was
compared to a strategy combining an extraction step on the NUCLISENS easyMAG platform (bioMérieux) with the
CMV R-gene kit (Argene) on 100 whole blood specimens collected from immunocompromised patients of the
University Hospital of Saint-Etienne, France.
Results: The overall agreement between the two strategies was 86% (kappa coefficient of 0.67); the 14 discrepant
results corresponded to low DNA loads. The 62 samples found positive with both tests were correlated (Pearson r
coefficient of 0.70, P < 0.01) despite an over quantitation of 0.25 log10 copies/ml with the easyMAG/Argene strategy
(P < 0.001). Very close results were also obtained with a commercial panel of 10 samples with CMV loads ranging
from 2.36 to 6.41 log10 copies/ml. The inter-run and intra-run variability was consistently lower with the QIAGEN
platform.
Conclusions: These results validate the performance of the QIAsymphony RGQ system for the routine quantitation
of CMV DNA. This fully-automated platform reduces the hands-on time and improves standardization, traceability
and quality control assessment.
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Cytomegalovirus (CMV) can cause both early and late
multi-organ disease post-transplantantation and remains
one of the most important complications after allogeneic
transplant. The detection of markers of CMV infection
in blood is a key feature of the virological surveillance of
immunocompromised patients [1]. Beside antigenemia
that is labour intensive, difficult to standardize and
requires an immediate analysis of the specimens, mo-
lecular methods based on quantitative real-time PCR
(RT-PCR) technology are considered to be the main* Correspondence: bruno.pozzetto@univ-st-etienne.fr
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reproduction in any medium, provided the oralternative option for diagnosis of CMV infection, allow-
ing decisions to be made regarding both implementation
of pre-emptive therapy, and monitoring response to
therapy [2-5]. In nucleic acid amplification techniques,
the extraction step is critical and needs to be carefully
evaluated notably when different extraction methods are
coupled to different PCR techniques [6].
The systematic use of molecular tools for the surveil-
lance of immunocompromised patients needs high
throughput machines able to monitor a large number of
whole blood or plasma specimens. Automated systems
integrating the extraction and amplification steps repre-
sent an attractive solution [6-8]. The recently commer-
cialised QIAsymphony RGQ system (QIAGEN S.A.S.,d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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QIAsymphony Sample Preparation (SP) and Assay Setup
(AS) modules respectively, together with the amplifica-
tion step on a Rotor-Gene Q (RGQ) RT-PCR machine
using the artus CMV QS-RGQ kit.
In this study, the fully-automated QIAsymphony RGQ
system was compared to the molecular strategy cur-
rently used in our laboratory for the determination of
CMV DNA load from whole blood specimens, which
combines extraction with the NUCLISENS easyMAG in-
strument (bioMérieux, Marcy l’Etoile, France) and amp-
lification using the CMV R-gene kit (Argene, Verniolle,
France) as previously validated in our hands [9].
Methods
Whole blood specimens
One hundred whole blood specimens were included in
the study. Samples were obtained from immunocom-
promised patients hospitalised at the University Hospital
of Saint-Etienne, France, for the following clinical pic-
tures scenarios: bone-marrow graft, kidney transplant-
ation or chronic HIV infection. For all of them, the
CMV DNA load was routinely evaluated as part of
standard patient care. The study was conducted on the
residual clinical specimens stored at −20°C. The research
was approved by the Ethics Committee of the University
Hospital of Saint-Etienne on the 30th of May 2012. For
the study, the samples were thawed, divided into 2 ali-
quots and tested by both systems on the same day. Spe-
cimens were then stored at 4°C until validated results of
quantitation with both amplification methods (<24h).
QCMD panel
The 2010 QCMD (Quality Control for Molecular
Diagnostics) program (Glasgow, UK) included 1 negative
and 9 positive (AD169 strain) specimens with viral loads
ranging from 230 to 2,552,701 copies/ml, diluted either
in CMV-negative human plasma or in virus transport
medium. The specimens were reconstituted, separated
in aliquot fractions and stored at −80°C as recom-
mended by the QCMD instructions. After thawing, they
were tested in the same way as clinical samples with
both extraction and amplification systems.
CMV DNA extraction and amplification
All the experiments were conducted with in vitro diag-
nosis (IVD) certified kits according to the manufacturers’
instructions.
QIAsymphony RGQ system
Just before extraction, 300 μl volumes of the whole blood
samples were manually transferred into 2-ml vials. The
tubes were placed into 24-tube capacity carrier racks and
loaded into the SP module. The extraction step wasperformed using the QIAsymphony DNA Mini Kit and
the Virus Blood 200 protocol with automated eluate dis-
pensing. The internal control of the artus CMV QS-RGQ
kit was added into ATE buffer and automatically distribu-
ted during the lysis of samples. With this protocol, 200 μl
volumes of whole blood were extracted and eluted into a
total volume of 90 μl, allowing a minimum accessible vol-
ume of 60 μl. The rack containing the elution tubes was
then automatically transferred to the AS module. A 30 μl
volume of the PCR mix prepared by the AS module using
the artus CMV QS-RGQ kit was automatically distributed
into RG 72 strip tubes (all reagent and eluate positions are
continually cooled) and after distribution of 20 μl of tem-
plate by the AS module, the RG 72 strip tubes were closed
and placed manually into the 72-well rotor of the
Rotor-Gene Q. The amplification step was performed
according to the manufacturer’s instructions. Each PCR
run included a set of quantitative calibrators correspond-
ing to 10, 100, 1000 and 10000 copies/μl of template; the
CMV DNA load was calculated from the standard curve
and expressed as the number of CMV DNA copies/ml of
whole blood (after calculating the input and output vol-
ume). The presence of PCR inhibition was detected when
the CT value for the internal control of the sample was
more than 3 cycles higher than the CT value for the in-
ternal control of a negative whole blood control.
Combination of extraction with NUCLISENS easyMAG
instrument and amplification with the CMV R-gene kit
Just before extraction, 200-μl volumes of the whole blood
samples were manually transferred into 4-ml cryotubes
containing 2 ml of lysis buffer. The whole extraction
process was performed on the NUCLISENS easyMAG in-
strument according to the previously validated protocol
[9]. With this protocol, 200 μl of whole blood was
extracted and eluted into a total volume of 50 μl. The elu-
ates were manually transferred into 2ml-tubes. Fifteen
micro liters of ready-to-use PCR mix of the CMV R-gene
kit and 10 μl of template were manually distributed into a
plate stored in a pre-cooled rack. The amplification step
was performed using an ABI7500 instrument (Applied
Biosystems) according to Argene’s instructions. Each PCR
run included a set of quantitative calibrators correspond-
ing to 5, 50, 500 and 5000 copies/μl of template; the CMV
DNA load was calculated from the standard curve and
expressed as the number of CMV DNA copies/ml of
whole blood. The presence of PCR inhibition was detected
when the CT value for the internal control of the sample
was more than 3 cycles higher than the CT value for the
internal control of a negative whole blood control.
Analytic performances of the QIAGEN workflow
The analytical performances of the QIAGEN workflow
were studied with frozen pooled blood samples from
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values. The limit of detection of the test was assessed
using seven 0.5-log10 dilution series of CMV DNA posi-
tive whole blood in CMV DNA negative blood to yield
concentrations ranging from 14 to 10000 CMV DNA
copies/ml. Each measure was tested on 5 replicate
aliquots.
The reproducibility of the QIAGEN system was deter-
mined in comparison with the easyMAG/Argene tech-
nique using 4 pools prepared from positive specimens
and exhibiting different DNA loads: one low (< 3 log10
copies/ml), two intermediate (between 3 and 4.5 log10
copies/ml) and one high (> 4.5 log10 copies/ml). For
each concentration, 8 frozen aliquots were tested, 4 for
intra-run reproducibility assay and 4 for inter-run re-
producibility assay (performed each on a different day).Correlation
The correlation analysis between the two systems was
performed using a set of paired aliquots of whole blood
specimens. The extraction and amplification steps were
performed the same day for the same sample with both
techniques.Statistical analysis
The lower limit of detection of the QIAGEN assay was
determined by probit analysis [10]. The agreement be-
tween methods’ results was tested by the kappa coeffi-
cient. Bivariate correlation analysis was performed with
the Pearson r coefficient and a two-tailed test of signifi-
cance. Differences in mean values were analysed by the
































Figure 1 Probit curve used to calculate the limit of detection of the Q
DNA positive whole blood in CMV DNA negative blood (lozenges) to yield
tested 5 times each. The limit of detection at 95% was extrapolated from tResults
Limit of detection and reproducibility of the QIAGEN
workflow
The limit of detection of the QIAGEN workflow, calcu-
lated by probit analysis, was 72 copies/ml, with a confi-
dence of 95% (Figure 1). By comparison to the easyMAG/
Argene system, the inter-run and intra-run variability was
consistently lower with the QIAGEN platform, notably for
the low and intermediate viral loads (Table 1).QCMD panel analysis
Ten samples belonging to the 2010 QCMD panel were
tested in duplicate with the two systems. The negative
sample was correctly assigned by both techniques. The
results for the 9 positive samples are illustrated in
Figure 2: the two systems exhibited the same range of
quantitation, despite the fact that the viral load was con-
sistently higher with the easyMAG/Argene method.
Correlation between the test systems in clinical
specimens
From the 100 clinical samples tested comparatively with
both systems, 3 needed to be tested again for an invalid
internal control value, 1 for easyMAG/Argene and 2 for
QIAGEN and could be validated after retest.
Of the 100 pairs of clinical samples, 62 were positive
with both methods and 24 were negative, which corre-
sponds to a substantial agreement of 86% (kappa coeffi-
cient of 0.67). Fourteen samples exhibited discrepant
results: 11 were tested positive with the QIAGEN platform
and negative with the easyMAG/Argene method and 3
samples exhibited the opposite result; all of these discrep-
ant results corresponded to viral loads < 2.5 log copies/ml.2 3 4
pies/ml
95%
IAsymphony RGQ method. Seven 0.5-log10 dilution series of CMV
concentrations ranging from 14 to 10000 CMV DNA copies/ml were
he sigmoid curve.
Table 1 Intra- and inter-run reproducibility of the two
strategies compared in the study on 4 replicates of each
pool
Mean (% coefficient of variation)*
QIAGEN system easyMAG/Argene combination
Intra-run Inter-run Intra-run Inter-run
Pool 1 2.30 (6.39) 2.47 (20.54) 2.82 (10.48) 2.48 (23.75)
Pool 2 3.51 (2.13) 3.53 (2.21) 4.54 (9.75) 4.00 (15.71)
Pool 3 3.70 (2.61) 3.58 (2.84) 4.34 (4.12) 4.33 (6.17)
Pool 4 4.83 (2.83) 4.72 (3.02) 5.12 (1.18) 5.12 (0.89)
* log10 copies/ml of whole blood.
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used to draw the correlation curve (Figure 3A) and the
Bland-Altman plot (Figure 3B). The Pearson r coefficient
was 0.70 (P < 0.01) and the mean difference in viral
loads was 0.25 log10 copies/ml to the benefit of the easy-
MAG/Argene strategy (P < 0.001). Samples correspond-
ing to low CMV DNA loads exhibited a high variability.
Among those with a CMV DNA load above 1000 cop-
ies/ml, 6 exhibited discrepancy of at least 0.5 log copies/
ml: 5 with CMV load higher by the easyMAG/Argene
method, one of them being below the mean of the differ-
ence – 2 SD in Figure 3B, and one with CMV load
higher by the QIAGEN platform.
The time necessary to complete a run was evaluated to
3.5 and 3.7 hours for the easyMAG/Argene strategy and
the QIAGEN system, respectively. However, the hands-onFigure 2 CMV DNA load obtained with both methods for the samples
QIAsymphony RGQ system and the easyMAG/Argene combination are repr
performed in duplicate. The horizontal bars show the theoretical viral loadstime was approximately of 0.3 hour for the QIAGEN sys-
tem versus 1 hour for the easyMAG/Argene strategy.
Discussion
The automation of molecular techniques performed on
a large scale is an important challenge in clinical vir-
ology. The QIAGEN workstation consisting of the
QIAsymphony SP and AS modules that has been re-
cently commercialised allows the successive achievement
of nucleic acid purification from various samples
(SP module) and the distribution of the extract com-
bined with master mix in PCR tubes (AS module). This
automated system has been recently evaluated for the
detection of enteric pathogens in faecal samples [11,12] and
the quantitation of hepatitis C viral load [13]. In addition,
three other studies evaluated the QIAsymphony SP extrac-
tion module alone for Epstein-Barr virus [14], HIV viral
load [15] and a panel of different viruses [16].
In this study, we evaluated the QIAGEN workstation
combined with the RGQ platform for the quantitation of
CMV DNA with the CMV artus CMV QS-RGQ kit from
200 μl of whole blood. Different versions of this amplifi-
cation kit have been shown to yield comparable results
of CMV DNA load with other molecular techniques
either in EDTA-plasma [17,18] or in whole blood [19].
Regarding the extraction step, previous studies evaluated
the QIAsymphony system for the quantitation of CMV
DNA in blood under different configurations: Raggam
et al. [20] tested the QIAsymphony SP module in combin-
ation with the R-gene kit from 200 μl of whole blood;of the 2010 QCMD program. Viral loads obtained with the
esented with diamonds and squares, respectively. The measures were
given by the manufacturer of the proficiency panel.
Figure 3 Correlation analysis using clinical samples. (A) Comparison of CMV DNA load by QIAsymphony RGQ platform and easyMAG/
Argene combination using whole blood samples (N=62). The results are expressed in log10 copies/ml. (B) Difference in quantitation between
QIAsymphony RGQ platform and easyMAG/Argene combination. Each point represents the difference observed between the results of the
2 methods against their mean. The standard deviation (SD) is 0.639.
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with the Roche kit from 1 ml of blood serum; finally,
Forman et al. [22] tested the same configuration as the
one used in the present study but from a different matrix
(1.2 ml of blood plasma). The limit of detection of these
different methodologies was 148, 90, and 23 CMV DNA
copies/ml, respectively; the value of 72 copies/ml obtained
in the current study with the QIAsymphony RGQ system
using a small volume (200 μl) of whole blood was very
close to that of the three former studies and to thatspecified in the QIAGEN handbook of the kit (164.6 cop-
ies/ml). It was much lower than that mentioned for the
R-gene technique in the manufacturer’s handbook but that
had been obtained with a MagNA Pure Compact auto-
mate (555 copies/ml).
By reference to the strategy routinely used in our la-
boratory that we had previously evaluated favourably [9],
the QIAsymphony RGQ system was well correlated, des-
pite a slight translation of CMV DNA loads to the bene-
fit of the easyMAG/R-gene couple. By contrast, a better
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system for low positive samples as illustrated by the dis-
tribution of positive discrepant samples (11 for the
QIAGEN platform and only 3 for the easyMAG/Argene
method). Furthermore, the inter-assay and intra-assay vari-
ability was shown to be lower with the QIAsymphony RGQ
system because of its complete automation, whereas the
easyMAG/R-gene combination includes several manual
steps (sample preparation, addition of magnetic silica,
transfer of eluates into microtubes, preparation and distri-
bution of PCR mix, calibrators and samples. . .).
Conclusion
In addition to fulfilling excellent technical performances
(linearity comprised between 1 × 103 and 5× 107 copies/ml,
and 95% limit of detection of 164.6 copies/ml for whole
blood according to the manufacturer’s specifications), the
QIAsymphony RGQ system offers a fully-automated work-
flow with reduction of hands-on time and improvement in
standardisation, traceability and quality control assessment.
It appears particularly adapted to the routine surveillance
of CMV DNA load in immunocompromised patients.
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